Differential involvement of serotonin 2A/C and thromboxane A2/prostanoid receptors in high- vs. low-shear rate arterial thrombosis in rabbits

J Pharmacol Exp Ther. 1997 Feb;280(2):761-9.

Abstract

Experiments performed in 226 pentobarbitone-anesthetized rabbits were designed to investigate the involvement of thromboxane/prostanoid and 5-hydroxytryptamine (5-HT)2A/C receptors during arterial thrombus formation in distinct low- and high-shear rate thrombosis models. Antithrombotic activities of the thromboxane/prostanoid receptor antagonist SQ 29,548 and two chemically distinct 5-HT2A/C receptor antagonists, ritanserin and ketanserin, were assessed first in low-shear rate (approximately 600 sec(-1)) arterial thrombosis, produced by insertion of a silk thread as thrombogenic substrate into the central section of an extracorporeal arteriovenous shunt established between the left carotid artery and the right jugular vein (n = 77), and second in high-shear rate (approximately 40,000 sec(-1)) arterial thrombosis, produced by critical stenosis and local endothelial injury of a carotid artery, characterized by cyclic flow reductions (CFRs) due to recurrent platelet aggregation and subsequent dislodgement of the thrombus (n = 149). Under low shear rate, SQ 29,548 (10-2500 microg/kg plus 10-2500 microg/kg/hr i.v.), but not ritanserin or ketanserin (both at 2500 microg/kg i.v.), dose-dependently inhibited thrombus formation. In contrast, under high shear rate, SQ 29,548 (10-160 microg/kg plus 10-160 microg/kg/hr i.v.) and both ritanserin and ketanserin (both at 10-2500 microg/kg i.v.) dose-dependently reduced CFR frequency, with ID50 values of 35 microg/kg (95% confidence limits, 24-58 microg/kg), 77 microg/kg (95% confidence limits, 40-132 microg/kg) and 89 microg/kg (95% confidence limits, 36-285 microg/kg) i.v., respectively. Furthermore, local infusion of the stable thromboxane A2 analog U-46619 (0.63 microg/kg/min) or 5-HT (20.8 microg/kg/min) proximal to the site of injury and stenosis in rabbits pretreated with either SQ 29,548 (40 microg/kg plus 40 microg/kg/hr i.v.) or ritanserin (160 microg/kg i.v.), respectively, restored CFR frequency to vehicle group levels in animals whose CFR frequency was previously reduced. The inhibitory activity of ketanserin and ritanserin on CFRs could not be attributed to 5-HT1B/D or alpha-1 adrenoceptor antagonist properties or to any hypotensive activity. These results provide firm evidence that thromboxane/prostanoid receptors are involved in arterial thrombosis in rabbits independently of the shear rate, whereas 5-HT2A/C receptors play a major role only in high-shear rate thrombus formation.

MeSH terms

  • Animals
  • Arteriovenous Shunt, Surgical
  • Aspirin / pharmacology
  • Blood Pressure / drug effects
  • Bridged Bicyclo Compounds, Heterocyclic
  • Carotid Arteries / pathology
  • Carotid Arteries / physiopathology
  • Carotid Arteries / surgery
  • Carotid Stenosis / pathology
  • Carotid Stenosis / physiopathology*
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / pathology
  • Endothelium, Vascular / physiopathology
  • Fatty Acids, Unsaturated
  • Heart Rate / drug effects
  • Hemodynamics / drug effects*
  • Hydrazines / pharmacology*
  • Jugular Veins / surgery
  • Ketanserin / pharmacology
  • Male
  • Oxadiazoles / pharmacology
  • Piperazines / pharmacology
  • Platelet Aggregation
  • Prazosin / pharmacology
  • Rabbits
  • Receptor, Serotonin, 5-HT2A
  • Receptor, Serotonin, 5-HT2C
  • Receptors, Prostaglandin / physiology*
  • Receptors, Serotonin / physiology*
  • Receptors, Thromboxane / physiology*
  • Ritanserin / pharmacology
  • Serotonin Antagonists / pharmacology
  • Stress, Mechanical

Substances

  • Bridged Bicyclo Compounds, Heterocyclic
  • Fatty Acids, Unsaturated
  • Hydrazines
  • Oxadiazoles
  • Piperazines
  • Receptor, Serotonin, 5-HT2A
  • Receptor, Serotonin, 5-HT2C
  • Receptors, Prostaglandin
  • Receptors, Serotonin
  • Receptors, Thromboxane
  • Serotonin Antagonists
  • Ritanserin
  • GR 127935
  • SQ 29548
  • Ketanserin
  • Aspirin
  • Prazosin